Targeted next-generation sequencing in chronic lymphocytic leukemia: A high-throughput yet tailored approach will facilitate implementation in a clinical setting

Haematologica

Volumn 100, Issue 3, 2015, Pages 370-376

  Sutton, Lesley Ann ^a   Ljungström, Viktor ^a   Mansouri, Larry ^a   Young, Emma ^a   Cortese, Diego ^a   Navrkalova, Veronika ^b   Malcikova, Jitka ^b   Muggen, Alice F ^c   Trbusek, Martin ^b   Panagiotidis, Panagiotis ^d   Davi, Frederic ^e   Belessi, Chrysoula ^f   Langerak, Anton W ^c   Ghia, Paolo ^g,h   Pospisilova, Sarka ^b   Stamatopoulos, Kostas ^a,i,j   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e SORBONNE UNIVERSITÉ   (France)

^f Nikea General Hospital Athens   (Greece)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^j G PAPANICOLAOU HOSPITAL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATM GENE; BIOINFORMATICS; BIRC3 GENE; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; DATA ANALYSIS; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HUMAN; KLHL6 GENE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); MYD88 GENE; NEXT GENERATION SEQUENCING; NOTCH1 GENE; POT1 GENE; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SF3B1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; XPO1 GENE; ALLELE; GENE EXPRESSION; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS;

MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; PHOSPHOPROTEIN; PROTEIN P53; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ALLELES; GENE EXPRESSION; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, NOTCH1; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84924666501     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.109777     Document Type: Article

References (37)

1. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
2. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
3. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365 (26):2497-2506.
4. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
5. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
6. Kohlmann A, Klein HU, Weissmann S, et al. The Interlaboratory RObustness of Nextgeneration sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25(12):1840-1848.
7. Mansouri L, Sutton LA, Ljungstrom V, et al. Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia. Leukemia. 2014;28(3):694-696.
8. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191-4196.
9. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
10. Landau DA, Carter SL, Getz G, et al. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia. 2014;28(1):34-43.
11. Rossi D, Khiabanian H, Spina V, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139-2147
12. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia. 2014 Oct 28. doi: 10.1038/leu.2014.297. [Epub ahead of print]
13. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012;97(3):437-441.
14. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012; 119(12):2854-2862.
15. Mansouri L, Cahill N, Gunnarsson R, et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia. Leukemia. 2013;27(2):512-514
16. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8): 1403-1412.
17. Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013;122(7): 1266-1270.
18. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013;27 (11):2196-2199.
19. Cortese D, Sutton LA, Cahill N, et al. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia. 2014;28(3):710-713.
20. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247-3254.
21. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2014 Jun 19. doi: 10.1038/leu.2014.196. [Epub ahead of print]
22. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
23. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121(3):468-475
24. Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol. 2013;792:109-31.
25. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108-117.
26. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456
27. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. 2011;17(1):10-12
28. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-576.
29. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3- 21 gene. Blood. 2005;105(4):1678-1685
30. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107(7):2889-2894.
31. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-270.
32. Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol. 2009;144(4): 492-506.
33. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99(1):300-309.
34. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood. 2005;106(9):3175-3182.
35. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448-5457.
36. Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012;97(1):142-146.
37. Flanagan SE, Patch AM, Ellard S. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet Test Mol Biomarkers. 2010;14(4):533-537.